Two routes to retatrutide are open in 2026, and how to get retatrutide comes down to which of them you qualify for: a Phase 3 trial site, the only source of pharmaceutical-grade material with medical supervision attached, or the research-chemical market, where it sells as research-use-only powder. Both are set out below, along with six named suppliers whose certificates and testing labs we opened on 13 August 2026.
Take the trial route if you qualify: a Phase 3 trial site is the single source of pharmaceutical-grade retatrutide, made under GMP and dosed under supervision, and Lilly's TRIUMPH programme recruits through ClinicalTrials.gov. Otherwise the research-chemical market is the route that exists, and one check decides which supplier to use — a batch-matched certificate carrying a mass-spectrometry identity line, not just an HPLC purity percentage. Only three of the ten suppliers we checked name their testing lab in their own site copy; on the rest you have to open the PDF and read the letterhead. There is no third route — no prescription, no pharmacy, no compounding — and the reasons are further down this page.
Route one: a clinical trial
Lilly's Phase 3 TRIUMPH program is running registrational trials for retatrutide. Trial sites recruit through ClinicalTrials.gov and their own networks. This is the only route to the actual investigational drug product — manufactured under GMP, with sterility and endotoxin assurance, dosed under supervision, with adverse events monitored and recorded.
The trade-off is that trials are trials: strict eligibility criteria, a real chance of randomization to placebo, scheduled visits, and protocol requirements. That is the price of the only supervised access that exists. Where the approval process stands covers the program in more detail.
Route two: the research-chemical market
Retatrutide is sold openly as a research compound. This is a legally distinct category from a drug: research-use-only material, labeled not for human consumption, sold for laboratory work without therapeutic claims. The labeling is the substantive basis for the sale rather than a disclaimer.
What you are buying is lyophilized powder with, at best, analytical characterization of that powder. What you are not buying — and this is the part that gets glossed over — is sterility assurance, endotoxin testing, GMP fill-finish, batch traceability into a regulatory system, or a regulator who will act if a lot fails. The full difference between research-grade and pharmaceutical-grade is worth reading before deciding this route is equivalent to the first one. It is not.
Retatrutide is the most substituted compound in the market. It is the most-searched peptide in the world, it is expensive, and almost no buyer can tell it apart from a cheaper 39-amino-acid peptide by looking. That combination is exactly the profile that attracts substitution and underfilling. Mass-spec identity confirmation on a batch-matched COA is the only thing that closes that gap — an HPLC purity figure alone tells you a peak is clean, not that it is the right peak.
What to check, in order
| Check | What good looks like |
|---|---|
| Batch-matched COA | Lot number on the certificate matches the lot number on your vial |
| Mass spec identity | Molecular weight confirmed, not just an HPLC purity percentage |
| Named lab | The testing laboratory is identified and checkable |
| RUO discipline | No dosing guidance, no therapeutic claims, no human-use marketing anywhere on the site |
| Cost per mg | Normalized across vial sizes before comparing suppliers |
The full walkthrough is in the retatrutide sourcing guide, and how to read a COA covers what each line on the certificate actually means.
Which suppliers publish what they claim?
Six suppliers on the research route, checked on their own storefronts on 13 August 2026 against a single question: does the documentation they advertise actually exist and open. This is a test of documentation practice rather than of retatrutide stock — no retatrutide price was verified for this table, so there is no price column. Pricing across this market is benchmarked on BPC-157, the most widely stocked compound, in the full ten-vendor comparison. Disclosure: Where To Buy Peptides earns a commission on purchases made through its links, and Peptriva is one of the vendors it links to — every cell below is a document you can open for yourself.
| Vendor | COA | Lab named | Ships free at |
|---|---|---|---|
| Peptriva Premium brand | Third-party, published | Freedom Diagnostics, on the product page | $200 |
| Sports Technology Labs | Third-party, published | MZ Biolabs and Colmaric, on the site and the document | $149 |
| Swiss Chems | Third-party, published | Janoshik, on the site | $100 |
| Core Peptides | Third-party, published | Vanguard Laboratory, on the document only | $200 |
| PS Peptides | Third-party, published | North American Diagnostics, on the document only | $200 |
| Red Rock Peptides | Claimed, none published | No lab named anywhere | Not offered |
Red Rock is in the table as the floor of the set rather than as a recommendation: it advertises “Verified With COAs” and publishes none at all. Two footnotes carry over from the BPC-157 price benchmark — Peptriva and Red Rock sell that compound in a 10 mg vial only, and Swiss Chems sells the arginine salt of BPC-157 rather than the plain peptide — so neither is like-for-like against a 5 mg row when you go and compare prices.
Whichever name you land on, run the identity check from the table above it. Retatrutide is a 39-amino-acid peptide, and a purity figure alone cannot tell you the peak it measured was the right one.
GLP3-R (retatrutide)
The triple-agonist reference compound used across the Jastreboff Phase 2 literature. Research use only — supplied with a batch-matched certificate of analysis.
Why the pharmacy routes are closed
Three routes get searched for constantly and none of them is available, all for the same underlying reason: retatrutide has no approval from any regulator, so there is no approved product for the system to move around.
- Prescription. A prescriber can only write for an approved product. Retatrutide has no approval from any regulator, so there is nothing to prescribe. This is not a matter of finding a willing doctor.
- Compounding pharmacies. The 503A route works from approved active pharmaceutical ingredients. Retatrutide is not one, so it is outside what a compounding pharmacy can lawfully prepare — unlike semaglutide and tirzepatide, which have had a complicated compounding history precisely because they are approved.
- Telehealth weight-loss clinics. These prescribe approved or compounded GLP-1s. A clinic offering retatrutide is not operating within either category.
All three open at once if retatrutide is approved, which is the single event worth tracking. Where the approval process stands is the page that follows it.
One last thing worth stating plainly: retatrutide's evidence base is a single Phase 2 trial in 338 people over 48 weeks, with a dose-dependent heart-rate signal that Phase 3 has not yet characterized. The demand for it has run a long way ahead of what is known about it. What the safety data does and does not show is the page to read before the sourcing one.
Frequently asked questions
How do you get retatrutide?
Two routes. A Phase 3 trial site is the only source of pharmaceutical-grade material with medical supervision attached, and the TRIUMPH program recruits through ClinicalTrials.gov. Outside a trial, the route is the research-chemical market, where it is sold as research-use-only material labeled not for human consumption. Not through a pharmacy — there is no approved product to dispense and no prescription to write.
Can a doctor prescribe retatrutide?
No. A prescriber can only write for an approved product, and retatrutide has no approval anywhere. It is also unavailable through 503A compounding, which works from approved active ingredients.
Can you join a retatrutide clinical trial?
The Phase 3 TRIUMPH program is Eli Lilly's, and trial sites recruit through ClinicalTrials.gov and their own networks. Eligibility criteria are strict and vary by trial. That is the only route to pharmaceutical-grade retatrutide with clinical supervision attached.
Is buying research retatrutide legal?
Buying research chemicals for laboratory use is legal in the US. The research-use-only labeling is the legal basis for the transaction, which is why a supplier who markets it for human use or supplies dosing guidance has stepped outside the category the sale depends on.
GLP3-R (retatrutide)
Research-use-only material, sold by the vial with batch documentation. Check the certificate of analysis against the batch you receive.
What to know now
- Only two routes to retatrutide exist, and they differ enormously in what comes with them.
- A Phase 3 trial site is the one source of pharmaceutical-grade material with medical care attached.
- Trial enrollment means meeting strict entry rules set by the study, not by the person applying.
- There is no third route to retatrutide: no prescription, no pharmacy, no compounding option.
- The other route sells it as research-use-only material, which is not the same thing as pharmaceutical grade.
References
- ClinicalTrials.gov. A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Are Overweight (TRIUMPH-1). clinicaltrials.gov retatrutide https://clinicaltrials.gov/search?cond=&term=retatrutide
- Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023). Triple–hormone-receptor agonist retatrutide for obesity — A phase 2 trial. New England Journal of Medicine, 389(6), 514–526. https://doi.org/10.1056/NEJMoa2301972
- U.S. Food and Drug Administration. (2013). Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only. FDA Guidance Document. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/distribution-vitro-diagnostic-products-labeled-research-use-only-or-investigational-use-only
- U.S. Food and Drug Administration. (2024). Section 503A of the Federal Food, Drug, and Cosmetic Act. https://www.fda.gov/drugs/human-drug-compounding/section-503a-federal-food-drug-and-cosmetic-act
- U.S. Food and Drug Administration. (2024). Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding